

◆ 基本情况

姓名：沈丽，医学博士，教授（硕士生导师）

邮箱：li.shen@hznu.edu.cn.

专业：内科学

◆ 研究领域

心力衰竭的预后评估和精准治疗

◆ 主讲课程

1. 医学导论
2. 内科学

◆ 主持教学科研项目和科研成果

◆ 教学科研项目

1. 国家科技重大专项子课题；早发冠心病患者介入无植入术后管理与随访体系的开发；2024.08-2028.07
2. 国家自然科学基金青年基金项目；基于当代射血分数降低的心力衰竭患者心脏性猝死风险预测模型的建立和验证；2022.01-2024.12.
3. 浙江省自然科学基金基础公益项目；尿白蛋白异常对慢性心力衰竭患者心血管和肾脏终点事件的临床应用价值研究；2023.01-2025.12.

◆ 科研成果

1. **Shen L**, Lee MMY, Jhund PS, et al. Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical Trials. *JAMA* 2024 Jun 25;331(24):2094-2104.
2. **Shen L**, Jhund PS, Petrie MC, et al. Declining Risk of Sudden Death in Heart Failure. *N Engl J Med.* 2017 Jul 6;377(1):41-51.
3. **Shen L**, Dewan P, Ferreira JP, et al. Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. *Circulation.* 2024 Dec 10;150(24):1913-1927.
4. Dewan P*, **Shen L***, Ferreira JP*, et al. Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved

Ejection Fraction: A Prespecified Analysis of

PARAGON-HF. *Circulation* 2024 Jul 23;150(4):272-282.

5. **Shen L**, Jhund PS, Docherty KF, et al. Accelerated and personalized therapy for heart failure with reduced ejection fraction. *Eur Heart J*. 2022 Jul 14;43(27):2573-2587.

6. **Shen L**, Claggett B, Jhund PS, et al. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HF_rEF from PARADIGM-HF and ATMOSPHERE. *Clin Res Cardiol*. 2021 Aug;110(8):1334-1349.

7. **Shen L**, Jhund PS, Anand IS, et al. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. *Clin Res Cardiol*. 2021 Aug;110(8):1234-1248.

8. **Shen L**, Jhund PS, Anand IS, et al. Incidence and Outcomes of Pneumonia in Patients With Heart Failure. *J Am Coll Cardiol*. 2021 Apr 27;77(16):1961-1973.

9. **Shen L**, Kristensen SL, Bengtsson O, et al. Dapagliflozin in HF_rEF patients treated with mineralocorticoid receptor antagonists: An analysis of DAPA-HF. *JACC Heart Fail*. 2021 Apr;9(4):254-264.

10. Solano S, Yang M, Tolomeo P, Kondo T, **Shen L**, et al. Clinical Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction and With Reduced Ejection Fraction According to the Prognostic Nutritional Index: Findings From PARADIGM-HF and PARAGON-HF. *J Am Heart Assoc*. 2025 Jan;14(1):e037782.

11. Matsumoto S, **Shen L**, Henderson AD, et al. Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction in PARADIGM-HF. *J Am Coll Cardiol*. 2024 Oct;84(18):1685-1700.

12. Matsumoto S, Henderson AD, **Shen L**, et al. Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function. *J Am Coll Cardiol.* 2024 Jun; 83(24):2426–2436.
13. Butt JH, **Shen L**, Inzucchi SE, et al. Dapagliflozin in Heart Failure, Type 2 Diabetes, and Neuropathy: A Meta-Analysis of DAPA-HF and DELIVER. *JACC Heart Fail.* 2024 Nov; 12(11):1946–1948.
14. Matsumoto S, Henderson AD, **Shen L**, et al. Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. *Eur J Heart Fail* 2025 Jan;27(1):124–139.
15. Matsumoto S, Yang M, **Shen L**, et al. Effects of sacubitril/valsartan according to polypharmacy status in PARAGON-HF. *Eur J Heart Fail.* 2024 May;26(5):1125–1138.
16. Dobbin SJH, **Shen L**, Petrie MC, Packer M, Solomon SD, McMurray JJV, Lang NN, Jhund PS. Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials. *Eur J Heart Fail.* 2023 Apr;25(4):488–496.